Watran Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.60 M
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.15 M
- Revenue Growth 12.46%
- Profit Growth 3.91%
- Ebitda 47.83%
- Net Worth 40.49%
- Total Assets 10.67%
About Watran Pharmaceuticals
Watran Pharmaceuticals Private Limited (WPPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 May 2019 (Five years and nine months 9 days old ). Its registered office is in Ambala, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.60 M.
The company currently has active open charges totaling ₹7.15 M.
Sujata and Sachin Kumar serve as directors at the Company.
Company Details
-
Location
Ambala, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24304HR2019PTC080095
-
Company No.
080095
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 May 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Watran Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sujata
|
Director | 24-Jun-2024 | Current |
|
Sachin Kumar
|
Director | Current |
Financial Performance of Watran Pharmaceuticals.
Watran Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.46% increase. The company also saw a slight improvement in profitability, with a 3.91% increase in profit. The company's net worth Soared by an impressive increase of 40.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Watran Pharmaceuticals?
In 2023, Watran Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sigmus Biotech Private LimitedSujata . is a mutual person
-
Alenrise Retail Private Limited
Sujata . is a mutual person
Charges (Loans)
₹7.15 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.50 Cr
- Hdfc Bank Limited : 0.21 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Oct 2022 | Hdfc Bank Limited | ₹2.15 M | Open |
| 31 Jan 2022 | Others | ₹5.00 M | Open |
How Many Employees Work at Watran Pharmaceuticals?
Unlock and access historical data on people associated with Watran Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Watran Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Watran Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
